Preclinical Development of a Selective Suppressor of Neuroinflammation for MCI/AD

Pharmacology, Toxicology and Pharmaceutical Science

1. Cytokine 100%
2. Nervous System Inflammation 100%
3. Alzheimer's Disease 100%
4. Mild Cognitive Impairment 100%
5. Diseases 66%
6. Pharmacodynamics 33%
7. Human Study 22%
8. Adverse Event 22%
9. Safety Pharmacology 11%
10. Mouse Model 11%
11. Drug Discovery 11%
12. Clinical Research 11%
13. Target Activity 11%
14. Pharmaceutical Chemistry 11%
15. Clinical Study 11%
16. Chemical Stability 11%
17. Absorption-Distribution-Metabolism-Excretion Toxicity 11%
18. Neurologic Disease 11%
19. Guanosine Phosphate 11%
20. Cognitive Defect 11%
21. Disease Exacerbation 11%
22. Central Nervous System Disease 11%
23. Tumor Growth 11%
24. Traumatic Brain Injury 11%
25. Pathophysiology 11%
26. Multiple Trauma 11%
27. Toxicology 11%
28. Comorbidity 11%